The Executive Yuan said that regenerative medicine brought a new treatment model and promoted the advancement of modern clinical 
medicine to an unprecedented height. For example, in 2006, the US Food and Drug Administration (FDA) approved two CAR-T cell 
therapies, which not only brought vitality to cancer patients, but also injected a strong heart into the field of cancer treatment.
The development of regenerative medicine can benefit more patients, reduce the suffering of cancer or other serious patients, 
improve the discomfort and inconvenience of the elderly, and also boost the clinical and industrial energy of domestic regenerative 
medicine, attract foreign investment in Taiwan. .
The Executive Yuan said that Taiwan and Japan are currently the only countries in the world to regard cell therapy as a medical 
technology development. They are leading the global development of the regenerative medical industry and making good use of Taiwan's 
medical advantages and clinical energy to become an Asian cell therapy center. Actively invest in the complete cell therapy 
management environment, regenerative medical innovation research and development, cell treatment peripheral product development, 
cell preparation plant construction and other environmental construction and make up for the industrial gap, and accelerate the 
demand driven by special measures to the upper and middle of the biomedical industry. Downstream.